Abstract:Background/Introduction Bleeding complications are still a major concern in anticoagulation therapy for venous thromboembolism (VTE), even in the direct oral anticoagulant (DOAC) era. Thus, the risk stratification of bleeding during anticoagulation therapy is essential, although most of currently available bleeding risk scores have been developed from patients receiving vitamin K antagonists, which could have limited validity in those receiving DOACs. Very recently, the DOAC Score has been developed to predict major bleeding in patients with atrial fibrillation on DOACs; however, the score has not yet been validated in patients with VTE. Purpose The present study aimed to evaluate the usefulness of the DOAC Score in patients with VTE, using a large-scale multicenter observational database of patients with VTE. Methods The COMMAND VTE Registry-2 is a multicenter registry enrolling 5197 consecutive acute symptomatic VTE patients among 31 centers in Japan between January 2015 and August 2020. The present study population was consisted of 3539 patients with VTE who received DOACs and had a calculated DOAC Score. The eligible patients were classified into 5 risk categories: very low (score 0–3), low (score 4–5), moderate (6–7), high (score 8–9), and very high (score ≥10). We used the Kaplan-Meier method to estimate the cumulative incidence and assessed the discriminatory ability of the DOAC Score for major bleeding at 1 year by calculating the area under the receiver operating characteristic curve. We also assessed the discriminatory ability of the VTE-BLEED and RIETE scores. Results In the present study population, the very low-risk group accounted for 1437 patients (41%), low-risk group for 828 (23%), moderate-risk group for 812 (23%), high-risk group for 326 (9.2%), and very high-risk group for 136 (3.8%). The proportion of anemia was highest in the very high-risk group (71%) and lowest in the very low-risk group (47%). The prevalence of active cancer was highest in the low-risk group (36%) and lowest in the very high-risk group (18%). During the first year of anticoagulation therapy, major bleeding occurred in 180 patients. The cumulative 1-year incidence of major bleeding seemed to be different according to the 5 groups, but the risks could not be well-stratified (Figure 1). The discriminating power of the DOAC Score was relatively low with a C-statistic of 0.52 (95% CI, 0.48–0.57) (Figure 2), while those of VTE-BLEED and RIETE scores were modest with C-statistics of 0.66 (95% CI, 0.60–0.73) and 0.67 (95% CI, 0.64–0.71), respectively. Conclusions The risk of 1-year major bleeding on DOACs in patients with VTE was not well-stratified according to the risk categories by the DOAC Score, which might suggest that patients with VTE have different risk factors for bleeding on DOACs as compared to those with atrial fibrillation. A new bleeding risk score for DOAC specifically in patients with VTE would be warranted in the future.Figure 1Figure 2

Risk Scores in Venous Thromboembolism Guidelines of ESC, ACCP, and ASH: An Updated Review

Assessing the Risk for Development of Deep Vein Thrombosis among Chinese Patients Using the 2010 Caprini Risk Assessment Model: A Prospective Multicenter Study.

Construction of Risk Assessment Model for Venous Thromboembolism after Colorectal Cancer Surgery: A Chinese Single-Center Study

[Anticoagulant therapy in venous thromboembolism and bleeding risk: focus on the use of predictive scores]

Systematic review of venous thromboembolism risk categories derived from Caprini score

Risk Assessment Scores for Cancer-Associated Venous Thromboembolic Disease

Internal Validation of a Risk Scoring System for Venous Thromboembolism After Total hip or Knee Arthroplasty

A review of venous thromboembolism risk assessment models for different patient populations: What we know and don't!

Risk Assessment Models for Venous Thromboembolism in Medical Inpatients

The evolution of the Caprini score

External Validation of Risk Scores for Predicting Venous Thromboembolism in Ambulatory Patients with Lung Cancer

Venous thromboembolism risk assessment of surgical patients in Southwest China using real-world data: establishment and evaluation of an improved venous thromboembolism risk model

Validation of two risk assessment models for venous thromboembolism in patients undergoing gynecologic surgery

A composite risk assessment model for venous thromboembolism

Comparison of the PADUA and IMPROVE scores in assessing venous thromboembolism risk in 42,257 medical inpatients in China

A Prospective Study Evaluating Patterns of Responses to the Caprini Score to Prevent Venous Thromboembolism After Interventional Treatment for Varicose Veins

Applying risk assessment models in general surgery: overview of our clinical experience

Validation of risk assessment models predicting venous thromboembolism in inpatients with AECOPD: a multicenter cohort study

Application of DOAC Score for the risk-stratification of major bleeding in patients with venous thromboembolism on direct oral anticoagulants: insight from the COMMAND VTE Registry-2

A Comprehensive Review of Risk Factors and Thrombophilia Evaluation in Venous Thromboembolism

Risk Factors and Assessment System Analysis of Venous Thromboembolism in Joint Surgery Patients